(Press-News.org) An international team of scientists is calling for urgent and temperature patterns in mountain regions after compiling evidence that high elevations could be warming faster than previously thought.
Without substantially better information, people risk underestimating the severity of a number of already looming environmental challenges, including water shortages and the possible extinction of some alpine flora and fauna, according to the research team, which includes Henry Diaz and Imtiaz Rangwala from CIRES, the Cooperative Institute for Research in Environmental Sciences at the University of Colorado Boulder. Both researchers are part of NOAA's Earth System Research Laboratory.
The team's report is published in the journal Nature Climate Change.
"There is growing evidence that high mountain regions are warming faster than lower elevations and such warming can accelerate many other environmental changes such as glacial melt and vegetation change," said lead author, Nick Pepin of the University of Portsmouth. But scientists urgently need more and better data to confirm this, because there are so few observations from 11,000 feet or higher, he and his co-authors said.
"It's understandable. Mountains are difficult to study, they are remote and often inaccessible, and it is expensive and often challenging to find ways of effectively monitoring what is happening," Pepin said. "Mountains are also very complicated landscapes, and have a wide variety of microclimates which makes it hard to see the overall picture."
The most striking evidence that mountain regions are warming more rapidly than surrounding regions comes from the Tibetan plateau, according to the new paper. There, temperatures have risen steadily over the past 50 years and the rate of change is speeding up. But masked by this general climate warming are pronounced differences at different elevations. For example, over the past 20 years temperatures above 13,000 ft (4,000 m) have risen nearly 75 percent faster than temperatures in areas below 6,500 ft (2,000 m).
The picture is more complicated in other regions. In the Rocky Mountains, for example, there are so few data that reach back more than a decade, researchers have not been able to make broad conclusions about warming trends at various altitudes, said CIRES' Diaz.
However sparse, existing monitoring has been a huge help to scientists trying to understand how various physical processes act to change climate at high altitudes, said Rangwala (see sidebar).
Records of weather patterns at high altitudes are "extremely sparse," the researchers found. The density of weather stations above 4,500 m is roughly one-tenth that in areas below that elevation. Long-term data, crucial for detecting patterns, doesn't yet exist above 5,000 m anywhere in the world. The longest observations above this elevation are 10 years on the summit of Kilimanjaro.
The team of scientists came together as part of the Mountain Research Initiative, a mountain global change research effort funded by the Swiss National Foundation. The team includes scientists from the UK, United States, Switzerland, Canada, Ecuador, Pakistan, China, Italy, Austria and Kazakhstan. Between them, they have studied data on mountain temperatures worldwide collected over the past 60-70 years.
Improved observations, satellite-based remote sensing and climate model simulations are all needed to gain a true picture of warming in mountain regions, said Raymond Bradley, a climatologist at the University of Massachusetts and one of the report's co-authors. "We are calling for special efforts to be made to extend scientific observations upwards to the highest summits to capture richer data on what is happening across the world's mountains," Bradley said. "We also need a strong effort to find, collate and evaluate observational data that already exists wherever it is in the world. This requires international collaboration."
The world's highest mountain, Mt Everest, stands at 8,848 m (29,029 feet). More than 250 other mountains, including Mt Elbrus in Russia, Mt Denali in Alaska, Mt Aconcagua in Argentina and Mt Kilimanjaro in Africa also all top the 5,000-m (16,000-feet) mark.
INFORMATION:
Shetland ponies' immune response to insect bites is helping scientists understand how people could be prevented from developing allergies.
The horse immune system can respond to midge bites in a way that prevents - rather than triggers - allergic reactions, researchers say.
The ponies' immune response to midge bites is similar to what happens in people with allergies, the team says. Understanding what triggers allergic reactions could help researchers come up with ways to stop people developing sensitivities.
It was previously thought that ponies which do not suffer ...
April 23, 2015, Vienna, Austria: A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver CongressTM 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis. The research was supported by the Wellcome Trust and the NIHR.
In the Liraglutide Efficacy and Action in NASH (LEAN) trial, overweight patients with biopsy-confirmed ...
April 23, 2015, Vienna, Austria: Phase III results revealed today at The International Liver Congress™ 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.
HIV co-infection more than triples the risk of hepatitis C-related liver disease, liver failure and liver-related death. Co-infection can also complicate the management of HIV infection.
In the ALLY-2 ...
April 23, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.
Using exome sequencing - a technique for sequencing all the protein-coding genes in a genome - the study identified relationships between environmental ...
April 23, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.
SOLAR 2 data are presented for 328 HCV genotype-1 or -4 treatment-naive or treatment-experienced ...
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.
A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another ...
April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver CongressTM 2015 has shown the devastating impact the infection has on their daily lives.
Research conducted with the Ministry of Health in Brazil questioned 1,217 people infected with hepatitis B or C in Europe and America using an online survey tool. The aim of the research ...
April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin ...
April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT). The data demonstrate that intravenous Civacir given both peri- and post-LT prevents HCV-reinfection in patients who also received antiviral therapy (AVT) before their transplant operation.
Civacir is a hepatitis C immune globulin (HCIG) produced from pooled plasma ...
April 23, 2015, Vienna, Austria: Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
An interim analysis of the study, revealed today at The International Liver Congress™ 2015, shows a significantly higher percentage of patients experienced NASH resolution and improvement in fibrosis after 48 weeks of treatment with silymarin compared to placebo.
NASH occurs when the liver becomes inflamed ...